Author

Gabriella Antonellis

Brigham and Women's HospitalORCID 0009-0006-4495-4772Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Adam NelsoniD· 1 shared Adrienne Gropper WaksiD· 1 shared Alexander P. GottliebiD· 1 shared Anthony G. LetaiiD· 1 shared Antonio J. AlmazaniD· 1 shared Brenda C. Chan· 1 shared Carlos Wagner S WanderleyiD· 1 shared Cheyanne Walker-WilliamsiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam NelsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Death and DifferentiationPeer-reviewedDec 26, 2025

Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms

Maria Davern, Cole J. Turner, Daryl Griffin…·Anthony G. Letai

This study identifies common survival mechanisms between drug-tolerant persisters and immunotherapy persisters, showing they share reduced mitochondrial apoptotic sensitivity and cross-resistance to therapies.

7 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 23, 2024

An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer

Kenichi Shimada, Daniel E. Michaud, Yvonne Xiaoyong Cui…·Jennifer L. Guerriero

This study identifies an estrogen receptor signaling program in HR+ breast cancer that suppresses immune responses by reducing T cell infiltration and HLA expression, suggesting therapeutic targets to enhance immunogenicity.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky